Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
The RNFT2/IL-3Rα axis regulates IL-3 signaling and innate immunity
Yao Tong, … , Yuan Liu, Bill B. Chen
Yao Tong, … , Yuan Liu, Bill B. Chen
Published January 28, 2020
Citation Information: JCI Insight. 2020;5(3):e133652. https://doi.org/10.1172/jci.insight.133652.
View: Text | PDF
Research Article Inflammation Pulmonology

The RNFT2/IL-3Rα axis regulates IL-3 signaling and innate immunity

  • Text
  • PDF
Abstract

Interleukin-3 (IL-3) receptor α (IL-3Rα) is the α subunit of the ligand-specific IL-3R and initiates intracellular signaling in response to IL-3. IL-3 amplifies proinflammatory signaling and cytokine storm in murine sepsis models. Here we found that RNFT2 (RING finger transmembrane-domain containing protein 2, also TMEM118), a previously uncharacterized RING finger ubiquitin E3 ligase, negatively regulated IL-3–dependent cellular responses through IL-3Rα ubiquitination and degradation in the proteasome. In vitro, IL-3 stimulation promoted IL-3Rα proteasomal degradation dependent on RNFT2, and we identified IL-3Rα lysine 357 as a ubiquitin acceptor site. We determined that LPS priming reduces RNFT2 abundance, extends IL-3Rα half-life, and sensitizes cells to the effects of IL-3, acting synergistically to increase proinflammatory signaling. In vivo, IL-3 synergized with LPS to exacerbate lung inflammation in LPS and Pseudomonas aeruginosa–challenged mice; conversely, IL-3 neutralization reduced LPS-induced lung injury. Further, RNFT2 overexpression reduced lung inflammation and injury, whereas Rnft2 knockdown exacerbated inflammatory responses in LPS-induced murine lung injury. Last, we examined RNFT2 and IL-3Rα in human lung explants from patients with cystic fibrosis and also showed that IL-3 is elevated in mechanically ventilated critically ill humans at risk for acute respiratory distress syndrome. These results identify RNFT2 as a negative regulator of IL-3Rα and show a potential role for the RNFT2/IL-3Rα/IL-3 axis in regulating innate immune responses in the lung.

Authors

Yao Tong, Travis B. Lear, John Evankovich, Yanwen Chen, James D. Londino, Michael M. Myerburg, Yingze Zhang, Iulia D. Popescu, John F. McDyer, Bryan J. McVerry, Karina C. Lockwood, Michael J. Jurczak, Yuan Liu, Bill B. Chen

×

Figure 5

The RNFT2/IL-3Rα axis regulates lung innate immunity and inflammation in vivo.

Options: View larger image (or click on image) Download as PowerPoint
The RNFT2/IL-3Rα axis regulates lung innate immunity and inflammation in...
(A and B) Immunoblot and densitometry analysis of RNFT2, IL-3Rα, and IL-3Rβ from mice intratracheally treated with control or LPS, as indicated. Data and mean ± SEM of 4 mice per group. (C) Cell concentration, (D) total protein analysis, and (E–G) ELISA analysis of (E) IL-6, (F) TNF-α, and (G) IL-1β from BALF of mice intratracheally treated with Lenti-empty or Lenti-RNFT2 and then treated with LPS and PBS or rIL-3, as indicated. Data and mean ± SEM pooled of 3 mice per group are from 2 independent experiments. (H) Cell concentration, (I) total protein analysis, and (J) ELISA analysis of IL-6 from BALF of mice intratracheally treated with Lenti-control shRNA or Lenti-RNFT2 shRNA and then treated with LPS and PBS or rIL-3, as indicated. Data and mean ± SEM pooled of 3 mice per group are from 2 independent experiments. (K and L) Histological analysis of lung samples from mice treated as indicated. Images are representative of all independent experiments. Scale bar: 100 μm. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by Student’s t test (B) or by 1-way ANOVA with Tukey’s post hoc test (C–J).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts